326 related articles for article (PubMed ID: 17921085)
1. PET/CT in oncology: for which tumours is it the reference standard?
Collins CD
Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S77-87. PubMed ID: 17921085
[TBL] [Abstract][Full Text] [Related]
2. PET in oncology: will it replace the other modalities?
Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) in clinical oncology. Part II].
Cabrera Villegas A; Gámez Cenzano C; Martín Urreta JC
Rev Esp Med Nucl; 2002 Apr; 21(2):131-47; quiz 149-51. PubMed ID: 11879626
[No Abstract] [Full Text] [Related]
4. Positron emission tomography for benign and malignant disease.
Visioni A; Kim J
Surg Clin North Am; 2011 Feb; 91(1):249-66. PubMed ID: 21184913
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of PET in oncology.
Rohren EM; Turkington TG; Coleman RE
Radiology; 2004 May; 231(2):305-32. PubMed ID: 15044750
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
7. Clinical role of positron emission tomography in oncology.
Bomanji JB; Costa DC; Ell PJ
Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography scanning is coming to a hospital near you soon!
Bashir H; Shabo G; Nunan TO
Clin Med (Lond); 2008 Apr; 8(2):134-9. PubMed ID: 18478853
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
Czech N; Brenner W; Kampen WU; Henze E
Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
[No Abstract] [Full Text] [Related]
11. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
12. [Current data and perspectives on positron emission tomography oncology-radiotherapy].
Lonneux M; Sibomana M; Pauwels S; Grégoire V
Cancer Radiother; 1999; 3(4):275-88. PubMed ID: 10486538
[TBL] [Abstract][Full Text] [Related]
13. [Positron-emission tomography in oncology].
Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
[TBL] [Abstract][Full Text] [Related]
14. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer.
Escott EJ
Radiol Clin North Am; 2013 Sep; 51(5):881-93. PubMed ID: 24010911
[TBL] [Abstract][Full Text] [Related]
15. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
[TBL] [Abstract][Full Text] [Related]
16. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
18. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
19. Detection of loco-regional recurrence in malignant head and neck tumors: a comparison of CT, MRI, and FDG PET-CT.
Kim ES; Yoon DY; Moon JY; Baek S; Han YM; Seo YL; Yun EJ
Acta Radiol; 2019 Feb; 60(2):186-195. PubMed ID: 29754496
[TBL] [Abstract][Full Text] [Related]
20. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies.
Li J; Zhou H; Zhang X; Song F; Pang X; Wei Z
Ann Palliat Med; 2020 Mar; 9(2):247-255. PubMed ID: 32233618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
